ArticleBMC surgery2026
Prognostic outcomes of pancreaticoduodenectomy with lymph node dissection in pancreatic and periampullary adenocarcinoma; a retrospective cohort study.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreaticoduodenectomy (PD) is a key surgical treatment for pancreatic and periampullary malignancies, but morbidity remains a challenge. Lymph node dissection improves outcomes by removing cancerous tissue and preventing metastasis. This study aims to assess survival rates, recurrence, and other postoperative outcomes.
methodsA retrospective cohort study was conducted on 390 patients who underwent PD with for pancreatic and periampullary adenocarcinoma between 2019 and 2023 at a single tertiary center. Non-adenocarcinoma histologies were excluded to ensure a homogeneous cohort. Follow-up data were available for 299 patients (76.7%), collected through hospital records and structured telephone interviews. Primary outcomes were overall survival, recurrence, and postoperative morbidity. Statistical analyses included Kaplan-Meier survival estimation, Cox proportional hazards modeling, and recurrence-free survival analysis. Fine-Gray competing risk regression and a prognostic nomogram were used for further risk stratification.
resultsAmong the 390 patients, the median overall survival was 3.5 years. The 1- and 3-year survival rates were 69.2% and 50.6%, respectively. The 5-year survival estimate (41.0%) should be considered preliminary, as it is based on extrapolation from immature follow-up data; mature 5-year outcomes require extended observation beyond the current study period. Multivariable analysis identified several key predictors of mortality: age ≥ 65 years (HR: 2.55, p < 0.001), pancreatic tumor origin (HR: 1.58, p = 0.009), positive lymph node status (HR: 2.37, p < 0.001), and fewer than 12 nodes removed (HR: 1.53, p = 0.018). Adjuvant chemotherapy reduced the risk of death (HR: 0.68, p = 0.033). Recurrence-free survival demonstrated the steepest decline during the first 36 months postoperatively.
conclusionLymph node status, chemotherapy, and tumor origin are crucial for predicting survival after PD. Proper lymph node evaluation and adjuvant chemotherapy are essential for improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.